PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Siegert, S.* ; Yu, Z. ; Wang-Sattler, R. ; Illig, T. ; Adamski, J. ; Hampe, J.* ; Nikolaus, S.* ; Schreiber, S.* ; Krawczak, M.* ; Nothnagel, M.* ; Nöthlings, U.*

Diagnosing fatty liver disease: A comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers.

PLoS ONE 8:e76813 (2013)
Verlagsversion PDF DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
BACKGROUND: To date, liver biopsy is the only means of reliable diagnosis for fatty liver disease (FLD). Owing to the inevitable biopsy-associated health risks, however, the development of valid noninvasive diagnostic tools for FLD is well warranted. AIM: We evaluated a particular metabolic profile with regard to its ability to diagnose FLD and compared its performance to that of established phenotypes, conventional biomarkers and disease-associated genotypes. METHODS: The study population comprised 115 patients with ultrasound-diagnosed FLD and 115 sex- and age-matched controls for whom the serum concentration was measured of 138 different metabolites, including acylcarnitines, amino acids, biogenic amines, hexose, phosphatidylcholines (PCs), lyso-PCs and sphingomyelins. Established phenotypes, biomarkers, disease-associated genotypes and metabolite data were included in diagnostic models for FLD using logistic regression and partial least-squares discriminant analysis. The discriminative power of the ensuing models was compared with respect to area under curve (AUC), integrated discrimination improvement (IDI) and by way of cross-validation (CV). RESULTS: Use of metabolic markers for predicting FLD showed the best performance among all considered types of markers, yielding an AUC of 0.8993. Additional information on phenotypes, conventional biomarkers or genotypes did not significantly improve this performance. Phospholipids and branched-chain amino acids were most informative for predicting FLD. CONCLUSION: We show that the inclusion of metabolite data may substantially increase the power to diagnose FLD over that of models based solely upon phenotypes and conventional biomarkers.  
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.730
1.063
8
8
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Whole-genome Association ; Insulin-resistance ; Nonalcoholic Steatohepatitis ; General-population ; Lipid-metabolism ; Index ; Epidemiology ; Genetics ; Risk ; Prediction
Sprache englisch
Veröffentlichungsjahr 2013
HGF-Berichtsjahr 2013
ISSN (print) / ISBN 1932-6203
Zeitschrift PLoS ONE
Quellenangaben Band: 8, Heft: 10, Seiten: , Artikelnummer: e76813 Supplement: ,
Verlag Public Library of Science (PLoS)
Verlagsort Lawrence, Kan.
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Molecular Epidemiology (AME)
Molekulare Endokrinologie und Metabolismus (MEM)
POF Topic(s) 30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
30201 - Metabolic Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-504200-003
G-505600-001
PubMed ID 24130792
DOI 10.1371/journal.pone.0076813
WOS ID WOS:000325810900087
Scopus ID 84885124263
Erfassungsdatum 2013-10-21
[➜Korrektur melden]